The FDA on October 29, 2024, granted accelerated approval to SCEMBLIX® (Asciminib) for adult patients with newly diagnosed Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) in Chronic Phase (CP). SCEMBLIX® is a product of Novartis AG.
Bottom Ad
Advertisement
Subscribe
